Laser zaps brain tumor, then immunotherapy attacks: new hope for glioblastoma?
NCT ID NCT07620548
First seen Jun 11, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. Doctors will use a laser to heat and destroy the tumor, then give an immunotherapy drug called cemiplimab to help the immune system fight any remaining cancer cells. About 99 participants will be randomly assigned to receive either this combo or standard chemotherapy. The goal is to see if the laser-immunotherapy combination can delay cancer growth and improve survival with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab (Libtayo) combined with laser interstitial thermal therapy (LiTT)
What this could lead to
If successful, this combination could offer a new, less toxic treatment option for recurrent glioblastoma, potentially extending survival without the harsh side effects of chemotherapy.
What could go wrong
This is a phase 2 trial with only 99 participants, so results are preliminary. The treatment may not improve outcomes, and there are risks from both the laser procedure and immunotherapy, such as brain swelling or immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.